Additionally, the 36-month beta value for TVTX is 0.71. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 5 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for TVTX is 75.74M and currently, short sellers hold a 12.27% ratio of that float. The average trading volume of TVTX on September 04, 2024 was 1.07M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TVTX) stock’s latest price update
Travere Therapeutics Inc (NASDAQ: TVTX)’s stock price has gone rise by 3.33 in comparison to its previous close of 9.60, however, the company has experienced a 9.49% increase in its stock price over the last five trading days. seekingalpha.com reported 2024-08-30 that Travere Therapeutics’ stock has been volatile due to Filspari’s failed Phase 3 trials, but a full FDA approval is possible next week that could boost its share price. Despite setbacks, Filspari’s unique dual-pathway mechanism and promising clinical data make FDA denial unlikely, supporting a bullish outlook. Travere’s financial health is precarious, with significant losses and a potential need for additional funding, but a buyout could be a favorable outcome.
TVTX’s Market Performance
Travere Therapeutics Inc (TVTX) has seen a 9.49% rise in stock performance for the week, with a 16.30% gain in the past month and a 29.34% surge in the past quarter. The volatility ratio for the week is 5.71%, and the volatility levels for the past 30 days are at 5.86% for TVTX. The simple moving average for the last 20 days is 11.67% for TVTX’s stock, with a simple moving average of 25.12% for the last 200 days.
Analysts’ Opinion of TVTX
Citigroup, on the other hand, stated in their research note that they expect to see TVTX reach a price target of $10, previously predicting the price at $7. The rating they have provided for TVTX stocks is “Buy” according to the report published on December 05th, 2023.
Citigroup gave a rating of “Neutral” to TVTX, setting the target price at $7 in the report published on November 20th of the previous year.
TVTX Trading at 9.64% from the 50-Day Moving Average
After a stumble in the market that brought TVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.04% of loss for the given period.
Volatility was left at 5.86%, however, over the last 30 days, the volatility rate increased by 5.71%, as shares surge +11.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +27.79% upper at present.
During the last 5 trading sessions, TVTX rose by +9.88%, which changed the moving average for the period of 200-days by +61.35% in comparison to the 20-day moving average, which settled at $8.94. In addition, Travere Therapeutics Inc saw 10.34% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TVTX starting from Cline Christopher R., who sale 54 shares at the price of $6.74 back on Apr 11 ’24. After this action, Cline Christopher R. now owns 70,849 shares of Travere Therapeutics Inc, valued at $364 using the latest closing price.
Dube Eric M, the CHIEF EXECUTIVE OFFICER of Travere Therapeutics Inc, sale 19,122 shares at $8.70 during a trade that took place back on Feb 01 ’24, which means that Dube Eric M is holding 350,600 shares at $166,435 based on the most recent closing price.
Stock Fundamentals for TVTX
Current profitability levels for the company are sitting at:
- -2.13 for the present operating margin
- 0.82 for the gross margin
The net margin for Travere Therapeutics Inc stands at -0.82. The total capital return value is set at -0.88. Equity return is now at value -582.60, with -59.56 for asset returns.
Based on Travere Therapeutics Inc (TVTX), the company’s capital structure generated 0.96 points at debt to capital in total, while cash flow to debt ratio is standing at -0.75. The debt to equity ratio resting at 25.3. The interest coverage ratio of the stock is -67.71.
Currently, EBITDA for the company is -331.81 million with net debt to EBITDA at -1.09. When we switch over and look at the enterprise to sales, we see a ratio of 6.37. The receivables turnover for the company is 6.52for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.04.
Conclusion
In conclusion, Travere Therapeutics Inc (TVTX) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
